U.S. stocks closed higher to end an abbreviated trading session and also extended a solid rally to close out the holiday shortened week. The markets’ grind higher was supported by the clarity offered from President-elect Joe Biden's administration taking shape, and even more so by the optimism surrounding multiple potentially effective COVID-19 vaccines. Economic and equity news was light. Treasury yields dipped as bond prices ticked higher, and the U.S. dollar slipped. Gold

U.S. equities finished out a rocky week lower, as investors weighed further signs of progress on the COVID-19 vaccine/treatment front, as well as implications of the recent spiking of new virus cases in the U.S. and Europe. The move by the Department of Treasury to allow some of the Fed's emergency lending programs to expire at the end of the year also garnered attention, but the market reaction was relatively tame. Meanwhile, Eli Lilly and Company received Emergency Use Auth

U.S. equities finished the last trading session of a wild week on a positive note, but were unable to secure a sweep of weekly gains. The markets have seen some large swings since Monday's rally, with optimism of a COVID-19 vaccine sparking some rotation into the hampered cyclically-natured and value stocks to the detriment of the high-flying mega-cap growth issues. Festering concerns regarding the implications of the persistent surge in new COVID-19 cases also had a hand in

The U.S. equity markets were able to shed some of their early losses and finish mixed and near the unchanged mark to cap off a strong week. Investors appeared to take a bit of a breather on the heels of the sharp rally this week that recouped last week's steep drop. Uncertainty surrounding the presidential outcome remained, as votes in key battleground states continue to be tallied. However, a stronger-than-expected October nonfarm payroll report seemed to keep sentiment buoy